Effective 01 Sep, Vyvanse
(lisdexamfetamine dimesilate), a
once-daily treatment for attention
deficit hyperactivity disorder
(ADHD), has been listed on the
Pharmaceutical Benefits Scheme
(PBS), the first ADHD treatment to
be listed in five years.
The product is described as a
12 hour long-acting medication,
suited to those patients needing
continuous coverage.
More than 200,000 Australian
children and adolescents are
thought to be affected by the
condition, according to the ABS.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Sep 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Sep 15
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
INTERN pharmacists from Monash University are set to join Victoria’s immunisation workforce under a new Secretary Approval by the Victorian Health Department.
VIRTUAL care delivered through telephone or video conference has now embedded itself as a core component of healthcare delivery in NSW, new market reports released today have revealed.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.